You are here: Industry Insights > Sanofi

News List

World’s First Dengue Vaccine Dengvaxia into Market Plight Mr. Nanguo
November 21, 2017
Performance of the dengue vaccine—Dengvaxia that is placed high hopes on by Sanofi is not optimistic, although the dengue is still running riot.
Sanofi, Novo back rare disease startup Inozyme in $49M round americanpharmaceuticacreview
November 16, 2017
The mission is to help babies with very rare disorders caused by mineral imbalances that can lead to overcalcification of soft tissues and undermineralization of bone, and can all too often cause death.
Sanofi collaborates with Principia Biopharma to develop multiple sclerosis drug biospectrumasia
November 13, 2017
Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and potentially other central nervous system (CNS) diseases
Sanofi pays $40M, commits $765M more for preclinical MS drug fiercebiotech
November 10, 2017
Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma.
Sanofi, Principia Agree To Develop Multiple Sclerosis Drug Candidate americanpharmaceuticacreview
November 10, 2017
Sanofi will develop Principia Biopharma experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases.
Bay Area's Principia Biopharma Scores $765M MS Licensing Deal With Drug Giant Sanofi biospace
November 10, 2017
SOUTH SAN FRANCISCO – A few months after striking a deal with AbbVie, Bay Area biotech Principia Biopharma has signed a deal worth up to $765 million with Sanofi for the development of a multiple sclerosis drug candidate.
Takeda’s dengue vaccine surpasses Sanofi’s in P2 trial pharmafile
November 08, 2017
Sanofi spent more than $1.5 billion and two decades to develop the first ever vaccine for dengue fever, only a few years after approval, however, it looks like it could be beaten, in terms of efficacy, by Takeda’s vaccine candidate.
Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease fiercebiotech
November 03, 2017
In Sanofi’s third-quarter results posted early this morning, the French Big Pharma says it is canning a phase 2 trial in idiopathic pulmonary fibrosis (IPF), following poor results from Roche and AstraZeneca.
Sanofi's maintains its guidance for 2017 despite disappoiting Q3 results BioSpace.com
November 03, 2017
The launch of Dupixent, pediatric vaccine sales and continued growth in Sanofi’s multiple sclerosis franchise were the strongest revenue drivers in the third quarter, Chief Executive Officer Olivier Brandicourt announced Wednesday as the company revealed
Sanofi, Regeneron’s biologic shines again in asthma trial pharmatimes
November 02, 2017
Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page